The American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP) proudly recognizes the recipients of its 2022 Master of the ACR and ARP designations, ACR Awards of Distinction, and ARP Awards of Merit and Appreciation. The awards will be given to this year’s winners at ACR Convergence 2022.
Dr. John Cush RheumNow
3 years 11 months ago
Actual video of needle arthroscopy in patients w/ suspected septic arthritis. https://t.co/tWgP4ZpFBJ https://t.co/cLWM48NBlA
A prospective cohort study of treatment and pregnancy outcomes in women with RA shows that TNF inhibitor use during pregnancy did not increase the risk of adverse pregnancy outcomes, but instead led to more positive outcomes such as fewer low-birth-weight deliveries.
Dr. John Cush RheumNow
3 years 11 months ago
Biomedical researchers are at their most creative/innovative EARLY in their career. Study based on 5.6 million papers (1980 to 2009). While least innovative drop out early; in the remaining, innovativeness tends to decline over their career.https://t.co/XY5xQfY8Ba https://t.co/Cs3MUr7qIi
Dr. John Cush RheumNow
3 years 11 months ago
Large retrospective claims data analysis of 86 964 adults w/ severe obesity and NAFLD: comparing bariatric surgery (35%) to those with nonsurgical care. Bariatric surgery lowered the risk of CVD by 49% https://t.co/xEVVQVEX30 https://t.co/gSUIeH1K0k
Dr. John Cush RheumNow
3 years 11 months ago
2 HIV+ pts with HLH (MAS) successfully Rx w/ JAKi - ruxolitinib. Both had high fevers, severe pancytopenia, hypofibrinogenemia, hypertriglyceridemia, & increased ferritin, BMBx Hemophagocytosis, splenomegaly. https://t.co/yGs7e4Ftgp https://t.co/cv9NX31bZr
Dr. John Cush RheumNow
3 years 11 months ago
ACR suggests a new ICD-10 code for "Pre-clinical RA".(PROPOSED NEW CODE: R76.81 “Abnormal rheumatoid arthritis-related immunologic findings without current or prior diagnosis of clinically apparent inflammatory arthritis.” This is not yet final. https://t.co/2Td0lYiUKg https://t.co/8m2OSfPWXz
Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry data indicated.
Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this pivotal trial.
Dr. John Cush RheumNow
3 years 11 months ago
Single center use IL-23 inhibitors (Guselkumab, Tildrakizumab, Risankizumab) in 80 PsA pts shows 1 yr survival 81%, w/ mean survival 61 wks (despite 95% Rx ≥1 prior biologics). 64% had PASI ≤2 at wks 12-17 and nearly 41% w/ PsA remission https://t.co/woDXhL44d5 https://t.co/6fvjzGlMEY
Dr. John Cush RheumNow
3 years 11 months ago
Record a Question or Comment...
Rheums: Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/rICbSJzPbk https://t.co/VIjlR6xlwQ
Dr. John Cush RheumNow
3 years 11 months ago
Tofacitinib shows promise in scleroderma
https://t.co/6qUGLlztBd https://t.co/Mk2x2HAkiO
Dr. John Cush RheumNow
3 years 11 months ago
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.
https://t.co/EGXslouPmC https://t.co/UVcdjzbxYp
Dr. John Cush RheumNow
3 years 11 months ago
Tofacitinib in 15 pts w/ early diffuse skin Scleroderma. Tofa downregulated STAT3 (macrophages, DCs) & IFN (fibroblasts) & MYOC/CCL19 (adventitial fibroblasts); well tolerated & trend to improved mRSS scores (ns) https://t.co/givh5j3m9z https://t.co/ms97tvQy5e
Dr. John Cush RheumNow
3 years 11 months ago
Comprehensive full-read review of #Baricitinib trials in treating COVID-19. 24 studies (16 retrospective, 5 prospective, 3 case control) studies & 3 larged RCTs show Bari as 24-38% better than comparators/SOC (few showed no change in mortality) https://t.co/2svMMX4wDw https://t.co/zoSGGZJYui
